Oppenheimer Reiterates Perform on Ambarella (AMBA)

Ambarella (AMBA) PT Lowered to $65 at Stifel

March 1, 2017 8:44 AM EST

Stifel lowered its price target on Ambarella (NASDAQ: AMBA) to $65.00 (from $82.00) while maintaining a Buy rating. 4Q revenue of $87.5mn was down 12.9% q/q and up 28.7% y/y, above the Street's $86.0mn.

Analyst Kevin Cassidy commented, "While we've been... More

Needham and Company Reiterates Hold Rating on Ambarella (AMBA) Following Strong F4Q17 Results; Outlook Lower on GoPro (GPRO) Loss

March 1, 2017 7:13 AM EST

Needham & Company analyst N. Quinn Bolton maintains Hold rating on Ambarella (NASDAQ: AMBA), as the company produced fiscal 2017 fourth quarter results above expectations, while acknowledging GoPro's (NASDAQ: GPRO) move to an alternative video processor will negative impact... More

Ambarella (AMBA) PT Lowered to $65 at Morgan Stanley

March 1, 2017 3:46 AM EST

Morgan Stanley lowered its price target on Ambarella (NASDAQ: AMBA) to $65.00 (from $70.00) while maintaining a Overweight rating.

Analyst Joseph Moore comments "While 24% customer GoPro has been a long term headwind, it will drop 80% this year as they move to an alternate... More

Dougherty & Co Upgrades Ambarella (AMBA) to Buy

March 1, 2017 3:08 AM EST

Dougherty & Co upgraded Ambarella (NASDAQ: AMBA) from Neutral to Buy with a price target of $75.00.

For an analyst ratings summary and ratings history on Ambarella click here. For more ratings news on Ambarella click here.

Shares of Ambarella closed at $58.95 yesterday.

... More

After-Hours Stock Movers 02/28: (DVAX) (BGFV) (DAR) Higher; (PANW) (SRPT) (ENPH) Lower (more...)

February 28, 2017 6:03 PM EST

Today's After-Hours Movers

Dynavax Technologies Corporation (NASDAQ: DVAX) 24.4% HIGHER; announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Dynavax's responses to the Complete Response Letter (CRL) issued by the FDA in November 2016 for the Biologics License Application for HEPLISAV-B, the company's vaccine candidate for immunization against hepatitis B infection in adults 18 years of age and older. The FDA has established August 10, 2017 as the Prescription Drug User Fee Act (PDUFA) action date.

Palo Alto Networks (NYSE: PANW)... More

Ambarella (AMBA) Tops Q4 EPS by 18c; Guides Q1 Revs Below Views

February 28, 2017 4:09 PM EST

Ambarella (NASDAQ: AMBA) reported Q4 EPS of $0.92, $0.18 better than the analyst estimate of $0.74. Revenue for the quarter came in at $87.5 million versus the consensus estimate of $86.07 million.

GUIDANCE:

Ambarella sees Q1 2018 revenue of $62.5-64.5 million, versus the... More